Sai Parenteral's (NSE:SAIPARENT) Total Operating Expense: ₹1,073 Mil (TTM As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAIPARENT Sai Parenteral's Ltd NSE:SAIPARENT
14 GF Score
Price ₹569.70
! 7 Warning Signs
View Full Analysis

What is Sai Parenteral's Total Operating Expense?

Sai Parenteral's NSE:SAIPARENT +5.28% 14 Total Operating Expense is ₹1,073 Mil as of Sep. 2025. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review.

Sai Parenteral's's Total Operating Expense for the six months ended in Sep. 2025 was ₹1,073 Mil. Sai Parenteral's's Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2025 was ₹1,073 Mil.

Sai Parenteral's Total Operating Expense Related Terms

Sai Parenteral's Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Sai Parenteral's's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Parenteral's Total Operating Expense Chart

Sai Parenteral's Annual Data
Trend Mar23 Mar24 Mar25
Total Operating Expense
221.27 330.45 1,930.81

Sai Parenteral's Semi-Annual Data
Mar23 Mar24 Mar25 Sep25
Total Operating Expense 0.00 0.00 0.00 1,072.51
NSE:SAIPARENT
14GF Score
Sai Parenteral's Ltd NSE:SAIPARENT
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sai Parenteral's Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹1,073 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of ₹1,073 Mil mean?
Sai Parenteral's (NSE:SAIPARENT) has a Total Operating Expense of ₹1,073 Mil as of Sep. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Sai Parenteral's and its competitors.
Is Sai Parenteral's' Total Operating Expense too high?
Sai Parenteral's' current Total Operating Expense is ₹1,073 Mil. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' Total Operating Expense compare to LLY and JNJ?
Sai Parenteral's' Total Operating Expense of ₹1,073 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Sai Parenteral's and its competitors. Sai Parenteral's's current Total Operating Expense is ₹1,073 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current Total Operating Expense of ₹1,073 Mil. The current Total Operating Expense is ₹1,073 Mil. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current Total Operating Expense is ₹1,073 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sai Parenteral's Business Description

Other Exchanges 544742:India
Address Plot No 39, 5th floor, Lavanya Arcade Jayabheri Enclave, Gachibowli, K.V.Rangareddy, Seri Lingampally, Hyderabad, TG, IND, 500032
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score

Get the complete analysis for NSE:SAIPARENT

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹569.70
Price